Welcome to our dedicated page for Bayer A G news (Ticker: BAYZF), a resource for investors and traders seeking the latest updates and insights on Bayer A G stock.
The BAYZF news page on Stock Titan aggregates recent announcements and press releases related to Bayer AG, a global life science company with core competencies in health care and nutrition. Investors and observers can use this feed to follow how Bayer communicates about its pharmaceutical pipeline, radiology developments, crop science launches and broader corporate strategy.
Recent Bayer news has highlighted updates on its Pharmaceuticals Division, including growth plans built around high-value products and a modality-rich pipeline in oncology, cardiology, neurology, immunology and women’s health. Releases describe pivotal approvals, regulatory milestones, and clinical data from programs in areas such as stroke prevention, heart failure, chronic kidney disease, prostate cancer, lung cancer and menopause-related vasomotor symptoms.
The news flow also covers Bayer’s activities in radiology and molecular imaging, such as clinical results for an investigational low-dose MRI contrast agent and the acquisition of investigational PET and SPECT tracers for diagnosing cardiac amyloidosis. In addition, company communications report collaborations in advanced modalities like cell and gene therapy and siRNA-based treatments, as well as progress in rare kidney diseases including Alport Syndrome.
Beyond human health, Bayer’s crop science releases describe new insecticides and seed treatments for crops such as canola and pulses, illustrating its role in agricultural inputs and food production. Together, these updates provide context on how Bayer pursues its stated mission of “Health for all, Hunger for none” across pharmaceuticals, diagnostics and agriculture. For anyone tracking BAYZF, this news page offers a centralized view of the company’s reported clinical milestones, product launches, partnerships and strategic initiatives over time.
Bayer (OTC:BAYRY) appointed Dr. Jost Reinhard as President of its Radiology business within the Pharmaceuticals Division, effective August 1, 2026. He will report to Stefan Oelrich and succeeds Nelson Ambrogio, who became President of Bayer U.S. Pharmaceuticals in May 2026.
Reinhard brings over 25 years of healthcare experience at Bayer across R&D, commercial roles in multiple countries, investor relations, and leadership of the Cell and Gene Therapy unit.
Bayer (OTC:BAYRY) announced global Consumer Health leadership changes on June 8, 2026 to support its Road to Billions growth strategy. The moves target faster decisions, stronger commercial execution, and expanded use of data.
New leaders include a global CMO, CDO, CCO, and a new U.S. Consumer Health President.
Bayer (OTC:BAYRY) reported full Phase III FIND-CKD results for KERENDIA (finerenone) in 1,584 adults with non-diabetic chronic kidney disease on standard of care. KERENDIA improved eGFR slope versus placebo (−3.3 vs −4.0 mL/min/1.73 m²/year; difference 0.7; p<0.001) and reduced a composite kidney-cardiovascular outcome (HR 0.77; 95% CI 0.60–0.99; p=0.043). Safety was generally similar, with serious adverse events 20.9% vs 21.2%. Hyperkalemia occurred in 17% vs 13.3%, with serious hyperkalemia <1% in both groups.
Bayer (OTC:BAYRY) will present new investigational data on KERENDIA (finerenone) at the 63rd European Renal Association Congress, June 3‑6, 2026, in Glasgow.
Highlights include first full Phase III FIND‑CKD results in non‑diabetic CKD and initial INFINITY pooled analysis across diabetic and non‑diabetic CKD populations.
Bayer (OTCMKTS:BAYRY) reported Phase II ARACOG head-to-head data showing patients on NUBEQA (darolutamide) had significantly less cognitive decline than those on enzalutamide over 24 weeks.
Median maximal cognitive decline in the primary endpoint MCCD was -15.8% with NUBEQA versus -36.1% with enzalutamide (p=0.009).
Bayer (OTC:BAYRY) will present new oncology data at the ASCO 2026 Annual Meeting in Chicago, May 29–June 2.
Sixteen abstracts cover prostate, breast, lung, salivary gland, renal cell, and colorectal cancers, including Phase II ARACOG results for NUBEQA and multiple studies of XOFIGO, HYRNUO, VITRAKVI, and STIVARGA.
Bayer (OTC:BAYRY) announced that the U.S. FDA accepted its supplemental New Drug Application and granted Priority Review for KERENDIA (finerenone) to treat adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).
The sNDA is backed by Phase III FINE-ONE data showing significant six‑month UACR reduction versus placebo and pooled Phase III CKD/T2D data. Kerendia is already approved for CKD with T2D and HF with LVEF ≥40%.
Bayer (OTC:BAYRY) received U.S. FDA Priority Review for its investigational oral Factor XIa inhibitor asundexian to prevent secondary stroke after non-cardioembolic ischemic stroke or TIA.
The NDA is supported by positive Phase III OCEANIC-STROKE results, which met primary efficacy and ISTH major bleeding safety outcomes; asundexian also has FDA Fast Track status.
Bayer (OTC:BAYRY) announced that the U.S. FDA has granted Priority Review to a supplemental new drug application for HYRNUO (sevabertinib) as first-line treatment for adults with locally advanced or metastatic HER2-mutated NSCLC who have not received prior therapy, based on preliminary Phase I/II SOHO-01 data.
Bayer (OTC:BAYRY) reported Phase II ARASEC data showing NUBEQA (darolutamide) plus ADT improved outcomes in U.S. patients with metastatic castration-sensitive prostate cancer (mCSPC) versus a matched ADT-alone historical control from CHAARTED.
The regimen reduced risk of progression or death by 71% and showed significant overall survival and rPFS benefits, with no new safety signals but notable design limitations.